Aclaris Therapeutics, Inc.(ACRS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,891 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ACRS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Aclaris Therapeutics, Inc. (ACRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACRS at 12.0/100 on a 32-signal composite quality model, placing it at rank #2,891 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.0) and revenue scale (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Aclaris Therapeutics, Inc. reports quarterly revenue of $1.6M, net income of $-21.5M, free cash flow of $-19.9M. Top institutional holders of ACRS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, BlackRock, based on the most recent SEC filings. ACRS trades on the Nasdaq exchange and files with the SEC under CIK 1557746. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aclaris Therapeutics, Inc. directly from SEC EDGAR. Aclaris Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 32 since 2022, currently 12.0 — a stable long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.6M
Net Income
Q2 2026
$-21.5M
Free Cash Flow
Q2 2026
$-19.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-58.2% YoYNet Income
+50.8% YoYOperating Income
+46.2% YoYEPS (Diluted)
+69.0% YoYTotal Assets
-27.2% YoYTotal Debt
Op. Cash Flow
-134.7% YoYFree Cash Flow
-133.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.8M -58.2% | $18.7M -40.1% | $31.2M +5.0% | $29.8M +340.1% | $6.8M +4.3% | $6.5M |
| Net Income | $-64.9M +50.8% | $-132.1M -49.3% | $-88.5M -1.8% | $-86.9M +4.4% | $-90.9M -78.1% | $-51.0M |
| Operating Income | $-76.4M +46.2% | $-141.9M -45.8% | $-97.4M -8.4% | $-89.9M -0.1% | $-89.7M -76.2% | $-50.9M |
| EPS (Diluted) | $-0.53 +69.0% | $-1.71 -34.6% | $-1.27 +4.5% | $-1.33 +16.9% | $-1.60 -33.3% | $-1.20 |
| Total Assets | $160.5M -27.2% | $220.3M +11.6% | $197.4M -22.5% | $254.6M +1.3% | $251.2M +254.9% | $70.8M |
| Total Debt | — | — | — | — | — | $10.7M |
| Operating Cash Flow | $-47.1M -134.7% | $-20.1M +74.4% | $-78.3M -15.9% | $-67.6M -29.6% | $-52.1M -34.9% | $-38.6M |
| Free Cash Flow | $-47.2M -133.8% | $-20.2M +74.6% | $-79.6M -16.8% | $-68.2M -30.0% | $-52.4M -34.2% | $-39.1M |
Get alerted when ACRS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aclaris Therapeutics, Inc. including:
Top Institutional Holders of ACRS
RA CAPITAL MANAGEMENT, L.P.
$67.3M12,723,026 shBML Capital Management, LLC
$63.3M11,975,000 shBlackRock, Inc.
$53.1M10,037,008 shDeep Track Capital, LP
$49.4M9,345,000 shVivo Capital, LLC
$35.4M6,694,637 shVANGUARD CAPITAL MANAGEMENT LLC
$30.8M5,817,866 shFrazier Life Sciences Management, L.P.
$26.1M4,925,374 shRock Springs Capital Management LP
$22.9M4,330,532 shADAGE CAPITAL PARTNERS GP, L.L.C.
$21.5M4,071,000 shDecheng Capital LLC
$21.4M4,041,736 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $67.3M | 12,723,026 |
| BML Capital Management, LLC | $63.3M | 11,975,000 |
| BlackRock, Inc. | $53.1M | 10,037,008 |
| Deep Track Capital, LP | $49.4M | 9,345,000 |
| Vivo Capital, LLC | $35.4M | 6,694,637 |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.8M | 5,817,866 |
| Frazier Life Sciences Management, L.P. | $26.1M | 4,925,374 |
| Rock Springs Capital Management LP | $22.9M | 4,330,532 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $21.5M | 4,071,000 |
| Decheng Capital LLC | $21.4M | 4,041,736 |
Companies Similar to ACRS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Monte Rosa Therapeutics, Inc.
Dianthus Therapeutics, Inc. /DE/
NewAmsterdam Pharma Co N.V.
Avalo Therapeutics, Inc.
uniQure N.V.
Arcus Biosciences, Inc.
Entrada Therapeutics, Inc.
Equillium, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ACRS on your watchlist
Track score changes the day Aclaris Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ACRS a good stock to buy?
13F Pro's AI-powered analysis of Aclaris Therapeutics, Inc. (ACRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACRS are available on the ACRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACRS is classified as a small company.
Which hedge funds own ACRS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aclaris Therapeutics, Inc.'s investment landscape.